Literature DB >> 17558331

Genotyping of Pneumocystis jiroveci pneumonia in Italian AIDS patients. Clinical outcome is influenced by dihydropteroate synthase and not by internal transcribed spacer genotype.

Antonella Valerio1, Elisa Tronconi, Francesca Mazza, Giovanna Fantoni, Chiara Atzori, Federica Tartarone, Piergiorgio Duca, Antonietta Cargnel.   

Abstract

BACKGROUND: Two Pneumocystis jiroveci independent genomic regions, internal transcribed spacer (ITS) 1 and ITS2, and dihydropteroate synthase (DHPS) gene have been used for typing a cohort of HIV-infected Italian patients with P jiroveci pneumonia (PcP).
METHODS: Bronchoalveolar lavage samples isolated from 207 HIV-infected adults were ITS and DHPS genotyped by DNA sequencing and by restriction fragment length polymorphism analysis, respectively. Mutant DHPS samples were cloned and ITS typed. Data on severity, treatment, and outcome of PcP were obtained by chart review.
RESULTS: High diversity with 46 different ITS genotypes was observed. At the DHPS locus, 9.1% of samples analyzed were found to be mutated. A correlation was observed between DHPS mutants and greater severity of PcP, as defined by higher lactate dehydrogenase (P = 0.015) and need for intubation (P = 0.002), and worse outcomes, as defined by failure of sulfa treatment (P = 0.04), death, and/or relapse of PcP (P = 0.008). There was a significant difference in ITS genotype patterns between DHPS wild-type and mutants (P = 0.028).
CONCLUSIONS: The present data suggest the absence of a correlation between P jiroveci ITS types and specific clinical characteristics. DHPS mutations correlate with possible failure of anti-P jiroveci sulfa therapy, and a trend of association is shown between DHPS mutations and some clinical PcP features.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17558331     DOI: 10.1097/QAI.0b013e3180decbe2

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  9 in total

1.  High prevalence of dihydropteroate synthase mutations in Pneumocystis jirovecii isolated from patients with Pneumocystis pneumonia in South Africa.

Authors:  Leigh Dini; Mignon du Plessis; John Frean; Victor Fernandez
Journal:  J Clin Microbiol       Date:  2010-03-29       Impact factor: 5.948

2.  Pneumocystis jirovecii infection and the associated dihydropteroate synthase (DHPS) and dihydrofolate reductase (DHFR) mutations in HIV-positive individuals from Pune, India.

Authors:  Arati Mane; Pankaj Gujar; Jipsi Chandra; Rahul Lokhande; Tilak Dhamgaye; Shivhari Ghorpade; Arun Risbud
Journal:  Mycopathologia       Date:  2014-09-30       Impact factor: 2.574

Review 3.  Diagnosing Pneumocystis jirovecii pneumonia: A review of current methods and novel approaches.

Authors:  Marjorie Bateman; Rita Oladele; Jay K Kolls
Journal:  Med Mycol       Date:  2020-11-10       Impact factor: 4.076

4.  Dihydropteroate synthase mutations in Pneumocystis pneumonia: impact of applying different definitions of prophylaxis, mortality endpoints and mutant in a single cohort.

Authors:  Christina Yoon; Anuradha Subramanian; Amy Chi; Kristina Crothers; Steven R Meshnick; Steve M Taylor; Charles B Beard; Leah G Jarlsberg; Gena G Lawrence; Melissa Avery; Alexandra Swartzman; Serena Fong; Brenna Roth; Laurence Huang
Journal:  Med Mycol       Date:  2013-03-08       Impact factor: 4.076

5.  Clinical significance and phylogenetic relationship of novel Australian Pneumocystis jirovecii genotypes.

Authors:  Sebastiaan J van Hal; Felix Gilgado; Tom Doyle; Joel Barratt; Damien Stark; Wieland Meyer; Jock Harkness
Journal:  J Clin Microbiol       Date:  2009-04-15       Impact factor: 5.948

Review 6.  A Molecular Window into the Biology and Epidemiology of Pneumocystis spp.

Authors:  Liang Ma; Ousmane H Cissé; Joseph A Kovacs
Journal:  Clin Microbiol Rev       Date:  2018-06-13       Impact factor: 26.132

7.  Low prevalence of Pneumocystis pneumonia (PCP) but high prevalence of pneumocystis dihydropteroate synthase (dhps) gene mutations in HIV-infected persons in Uganda.

Authors:  Steve M Taylor; Steven R Meshnick; William Worodria; Alfred Andama; Adithya Cattamanchi; J Lucian Davis; Samuel D Yoo; Patrick Byanyima; Sylvia Kaswabuli; Carol D Goodman; Laurence Huang
Journal:  PLoS One       Date:  2012-11-16       Impact factor: 3.240

8.  Clinical characteristics of Pneumocystis pneumonia in non-HIV patients and prognostic factors including microbiological genotypes.

Authors:  Yasufumi Matsumura; Yuichiro Shindo; Yoshitsugu Iinuma; Masaki Yamamoto; Michinori Shirano; Aki Matsushima; Miki Nagao; Yutaka Ito; Shunji Takakura; Yoshinori Hasegawa; Satoshi Ichiyama
Journal:  BMC Infect Dis       Date:  2011-03-25       Impact factor: 3.090

9.  Pneumocystis jirovecii genotype associated with increased death rate of HIV-infected patients with pneumonia.

Authors:  Meja Rabodonirina; Laetitia Vaillant; Patrick Taffé; Aimable Nahimana; René-Pierre Gillibert; Philippe Vanhems; Philippe M Hauser
Journal:  Emerg Infect Dis       Date:  2013-01       Impact factor: 6.883

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.